Ayman Nassar
About Ayman Nassar
Ayman Nassar is a Senior Disease Area Specialist in Cardiovascular at Bristol-Myers Squibb, with a background in oncology and extensive experience in the UK healthcare system.
Company
Ayman Nassar currently works at Bristol-Myers Squibb. He joined the company in February 2020 and serves as a Senior Disease Area Specialist focusing on Cardiovascular in New Jersey, United States. Bristol-Myers Squibb is a global biopharmaceutical company known for its research and development in various disease areas, including cardiovascular diseases.
Title
Ayman Nassar holds the title of Senior Disease Area Specialist - Cardiovascular at Bristol-Myers Squibb. His role involves specialized work in cardiovascular disease, aiming to advance medical treatments and collaborate with other specialists in this field.
Education and Expertise
Ayman Nassar studied at Newcastle University, where he pursued a Master of Science in Biology from 2015 to 2018. He also attended the University of Exeter, Plymouth University, studying Education from 2011 to 2012. He completed his high school education at Althagher High School in Jeddah, KSA, from 1990 to 1993. In addition to his formal education, he has a keen interest in immunotherapy, focusing on building a diverse skill set in cancer medicine and education.
Background
Before his current role, Ayman Nassar held several positions within the healthcare sector in the United Kingdom. He served as an Oncology Specialist at Royal Devon and Exeter NHS Trust for 8 years and was involved in various roles such as Senior House Officer and Locum. He worked as an Honorary Fellow at Peninsula Medical School for 7 years, and also gained experience at North Devon District Hospital as both a Senior House Officer and House Officer.
Collaborative Efforts in Oncology
Ayman Nassar actively seeks collaboration opportunities with other specialists in the field of oncology. His experience in immunotherapy and cancer medicine, combined with his extensive background in different roles within the NHS and medical schools, positions him as a valuable collaborator in advancing oncology research and treatments.